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Bacteroides fragilis can be classified into division I (cfiA negative) and division II (cfiA positive) isolates.
Division II isolates have a silent chromosomal carbapenemase gene (cfiA) that can become overexpressed
by an insertion of a mobile genetic element and thus develop a phenotypic resistance to carbapenems.
Aims of our study were (i) to determine the prevalence of B. fragilis division II (cfiA positive) isolates
among blood stream and non-blood stream isolates from two major Slovenian tertiary-care hospitals and
(ii) to assess its influence on phenotypic resistance to imipenem. Consecutive non-duplicate B. fragilis
isolates from blood stream and non-blood stream specimens were included in the analysis from 2015 to
2017 period. Data from laboratory information system were matched with mass spectra obtained with
Microflex LT instrument and MALDI Biotyper 3.1 software (Bruker Daltonik, Bremen, Germany). All mass
spectra were reanalyzed using Bruker taxonomy library. Spectra with a log(score)> 2.0 were further
analyzed with cfiA library that separates B. fragilis division I and II isolates based on a log(score) value
difference of >0.3. Minimal inhibitory concentrations (MICs) for imipenem were determined with Etest
(bioMerieux, Marcy l’Etoile, France), using supplemented Brucella agar and EUCAST breakpoints
(S 2mg/L, R> 8mg/L). Altogether 623 consecutive B. fragilis isolates were included in the analysis; 47
(7.5%) were isolated from blood stream and 576 (92.5%) from non-blood stream specimens. Among all
study isolates, 51 (8.2%) proved to belong to division II (cfiA positive). The proportions of division II
isolates among blood stream and non-blood stream isolates were 14.9% and 7.6%, respectively (p¼ 0.081,
ns). In total, 1.3% (n¼ 8) were non-susceptible to imipenem (MIC >2mg/L); 4.3% (n¼ 2) among blood
stream and 1% (n¼ 6) among non-blood stream isolates. All imipenem resistant isolates belonged to
division II. Modal MICs (MIC range) were 0.064mg/L (0.016 mg/L-2 mg/L) and 0.125mg/L (0.064 mg/L-
32mg/L) for division I and II isolates, respectively.
© 2019 Elsevier Ltd. All rights reserved.1. Introduction
Bacteroides fragilis is an important human gut commensal bac-
terium which is also the single most common anaerobic isolate
from clinical specimens and can cause a plethora of different hu-
man infections such as skin and soft tissue, intraabdominal in-
fections and sepsis [1e3]. This organism is inherently poorly
susceptible to a majority of b-lactam antibiotics but was untily and Immunology, Medical
ubljana, Slovenia.
rica).
High prevalence of division
Anaerobe, https://doi.org/10.1recently almost fully susceptible to b-lactam/b-lactamase inhibitor
combinations and carbapenems [4,5]. It can be classified into di-
vision I (cfiA negative) and division II (cfiA positive) isolates.
The existence of carbapenem-resistant B. fragilis was first
detected in the late 1980s, soon after the introduction of carbape-
nems into clinical practice [6,7]. These strains produced Znþ
dependent metallo-b-lactamase that was able to hydrolyze a ma-
jority of b-lactams, including cephamycins and carbapenems [6],
and was coded by the chromosomally mediated cfiA (also known as
ccrA) gene [8,9]. It is mostly regarded as a silent gene with a low
level of constitutive expression, but its expression can be upregu-
lated following the insertion of an insertion sequence (IS) elementII (cfiA positive) isolates among blood stream Bacteroides fragilis in
016/j.anaerobe.2019.01.011
S. Jeverica et al. / Anaerobe xxx (xxxx) xxx2with an efficient promotor immediately upstream of the gene. This
insertion is a one-step genetic event that can occur following
antibiotic therapy with carbapenems and is considerably stable
even without further selection pressure with carbapenems
[10e12]. However, the IS element insertion can explain only about
one half of high-level carbapenem resistance in cfiA positive strains
while the other half may have other genetic background such as
mutations leading to porin loss, upregulation of drug efflux,
reduced affinity of penicillin-binding proteins or by some other less
well characterized mechanisms [12,13]. Furthermore, it was shown
that cfiA positive isolates belong to a distinct homology group of
B. fragilis also referred to as division II isolates and that division I
B. fragilis are cfiA negative [14,15]. These two groups of B. fragilis
isolates are not formal taxonomic entities so far, however they may
represent two distinct genospecies or may even represent two
groups of B. fragilis isolates not yet separated at the species level
[15]. Other chromosomal b-lactamases have been described in
B. fragilis. CepA is the most widespread among them and confers
resistance to penicillins and cephalosporins (except cephamycins).
It is inhibited by several b-lactam inhibitors including clavulanic
acid and tazobactam and is the reason why b-lactam/b-lactamase
inhibitor combinations retain their activity against most B. fragilis
isolates. CepA is mainly associated with division I isolates [14,15].
CfxA is a cephalosporinase that is most active against cephaloridine
and can be found in several other Bacteroides species in addition to
B. fragilis [16,17].
It is unclear whether there are any clinical consequences
following an infection with specific division I or II of B. fragilis.
Furthermore, there is a paucity of data regarding the epidemiology
and antimicrobial resistance of B. fragilis in Slovenia and in general.
Aims of our study were (i) to determine the prevalence of B. fragilis
division II (cfiA positive) isolates among blood stream and non-
blood stream isolates from two major Slovenian tertiary-care hos-
pitals and (ii) to assess its influence on phenotypic antimicrobial
resistance to imipenem.
2. Methods
2.1. Clinical setting and Bacteroides fragilis isolates
The study was performed at the Institute of Microbiology and
Immunology, Medical Faculty, University of Ljubljana, the largest
Slovenian microbiology laboratory that serves bacteriological
samples from two major tertiary-care hospitals in the area, (i) the
University Medical Centre Ljubljana and (ii) the Institute of
Oncology Ljubljana, comprising in total around 2400 beds.
The study period was 18 months long, from 07/2015 to 12/2017.
From that period, we retrospectively extracted data for all B. fragilis
isolates from the Institute's laboratory information system. The
initial spreadsheet included 1163 isolates with basic patient de-
mographic data, information on collection date, specimen type and
antimicrobial susceptibility results, including the MIC values for 5
antimicrobial agents (penicillin, co-amoxiclav, imipenem, clinda-
mycin and metronidazole). From this spreadsheet, we excluded all
duplicate isolates, which were defined as isolates from the same
patient and specimen type isolated within 30 days period and
isolates with identification log(score) < 2.0. We further labeled all
isolates from blood as blood stream and isolates from other spec-
imen types, majority of which were from wounds and abdominal
region, as non-blood stream. The final spreadsheet included 623
consecutive non-duplicate B. fragilis isolates.
2.2. Identification and antimicrobial susceptibility testing
All isolates were identified with MALDI-TOF mass spectrometryPlease cite this article as: S. Jeverica et al., High prevalence of division
Slovenia as determined by MALDI-TOF MS, Anaerobe, https://doi.org/10.1(MS), using Microflex LT instrument and MALDI Biotyper 3.1 soft-
ware (Bruker Daltonik, Bremen, Germany). We recovered all
B. fragilis spectra from the Institute's archive and reanalyzed them
with (i) the regular taxonomy library and, furthermore, spectra that
corresponded to B. fragilis with a log(score)> 2.0 with (ii) the “cfiA
library” that separates B. fragilis division I and II isolates based on a
log(score) value difference of >0.3, following the recommendations
of themanufacturer. The “cfiA library”, provided to us by the Bruker,
has two entities (cfiA positive and cfiA negative) and, was validated
previously [15]. The delineation between the two divisions of
B. fragilis isolates thus involved manipulation and reanalysis of the
initially obtained MALDI spectra.
Minimal inhibitory concentrations (MICs) were determined
with Etests (bioMerieux, Marcy l’Etoile, France) using supple-
mented Brucella agar as previously described [3]. EUCAST break-
points (version 7.1) for penicillin (S 0.25mg/L, R> 0.5mg/L), co-
amoxiclav (S 4mg/L, R> 8mg/L), imipenem (S 2mg/L,
R> 8mg/L), clindamycin (S 4mg/L, R> 4mg/L) and metronida-
zole (S 4mg/L, R> 4mg/L) were used for category interpretation.
B. fragilis ATCC 25286 was used for quality control of the entire
susceptibility setting on a weekly basis.
2.3. Molecular confirmation of cfiA gene and IS element
During the study period, we prospectively collected B. fragilis
isolates with imipenem MIC 0.25mg/L for further molecular
characterization and thus for confirmation of MALDI-TOF MS cfiA
typing results. Isolates were cryopreserved and transported to the
Institute of Clinical Microbiology, University of Szeged, Szeged,
Hungary, for cfiA gene and activating IS element detection. These
experiments were performed as previously described [15], except
for B. fragilis ID 7, where the upstream activating IS was detected by
inverse PCR. This procedure has three steps: (i) digestion of
genomic DNA, (ii) ligation to form circular DNAs and (iii) PCR of the
inversely ligated DNA. This inverse PCR was essentially carried out
as described previously with the following specificities: Bsu RI re-
striction digestion of chromosomal DNA, I-cfiA-1 (5’-CCA-
TACCCCATCCTTCGATT) and I-cfiA-2 (5’-ATTCACCGATTCACTGACCG)
inverse primers and 94 C 3min; 94 C 15 s, 56 C 30 s, 72 C 3min,
35x; 72 C 7min inverse PCR cycles [26].
2.4. Statistical methods
Basic descriptive statistics was used to describe the sample
parameters. Pearson Chi-square test was used for comparison of
cfiA positivity prevalence between blood stream and non-blood
stream B. fragilis isolates. SPSS Statistics version 23 (IBM Corpora-
tion, Armonk, New York, USA) and Microsoft Excel version 16
(Microsoft Corporation, Redmond, Washington, USA) were used for
data manipulation and statistical analysis. Statistical significance
was set to p-value of <0.05.
3. Results
Altogether, 623 consecutive non-duplicate B. fragilis isolates
were included in the final analysis, belonging to 596 patients; mean
age 66 years (standard deviation: 19 years, range: 0e99 years) of
which 48.7% (n¼ 290) were females. 7.5% of the isolates (n¼ 47)
were from blood stream specimens (blood cultures) and 92.5%
(n¼ 576) were from non-blood stream specimens: 74.2% (n¼ 462)
from wounds and 18.3% (n¼ 114) from abdominal specimens.
With regard to division I and II distribution, 91.8% (n¼ 572) of
our B. fragilis isolates were division I (cfiA negative) and 8.2%
(n¼ 51) were division II (cfiA positive). The proportions of division
II isolates among blood stream and non-blood stream isolates wereII (cfiA positive) isolates among blood stream Bacteroides fragilis in
016/j.anaerobe.2019.01.011
Table 1
B. fragilis isolates and phenotype distribution.
B. fragilis isolates Number Proportion Division IIb
n % n (%)
Blood stream 47 7.5 7 (14.9)c
Non-blood stream 576 92.5 44 (7.6)c
Abdominala 114 18.3 5 (4.4)
Wounda 462 74.2 39 (8.4)
Total 623 100 51 (8.2)
a Non-blood stream isolates.
b Division II (cfiA positive) based on MALDI-TOF MS typing.
c The difference between blood stream and non-blood stream (abdomi-
nalþwound) isolates is statistically non-significant (p¼ 0.081). Fig. 1. Relative imipenem MIC distribution among division II (cfiA positive) and divi-
sion I (cfiA negative) B. fragilis isolates (n¼ 623).
S. Jeverica et al. / Anaerobe xxx (xxxx) xxx 314.9% (n¼ 7) and 7.6% (n¼ 44), respectively. The difference was
substantial; however, it did not reach statistical significance
(p¼ 0.081). Table 1 shows the distribution of division II isolates
among blood stream and non-blood stream B. fragilis isolates.
Antimicrobial susceptibility results are shown in Table 2. Non-
susceptibility rates (i.e. resistant and intermediate category com-
bined) among all isolates for penicillin, co-amoxiclav, imipenem,
clindamycin and metronidazole were 99.8%, 8.3%, 1.3%, 16.7% and
0%, respectively. In the subgroup analysis, there was significant
difference in clindamycin non-susceptibility rates between blood
stream (29.8%) and non-blood stream (15.6%) isolates (p¼ 0.012)
and significant difference in non-susceptibility rates among divi-
sion I and II isolates for co-amoxiclav (6.8% vs 25.5%; p< 0.001) and
imipenem (0% vs. 15.7%; p< 0.001), respectively. All imipenem
resistant isolates belonged to division II. Modal imipenemMICs and
MIC ranges were 0.064mg/L and 0.016 mg/L-2 mg/L for division I
isolates and 0.125mg/L and 0.064 mg/L-32mg/L for division II
isolates. Fig. 1 shows relative MIC distribution for both division I
and II isolates.
A selection of 30 non-duplicate B. fragilis isolateswith imipenem
MIC 0.25mg/L was available for further molecular characteriza-
tion and detection of cfiA gene and IS element, and thus confir-
mation of MALDI-TOF MS cfiA typing results. Among them, 24
isolates had MIC 2mg/L and were thus susceptible, two isolates
had MIC¼ 4mg/L (intermediate) and four had MIC 32mg/L
(resistant). Seventeen isolates belonged to division II based on
MALDI-TOF MS typing and all were confirmed to also harbor the
cfiA gene. The concordance between MALDI-TOF MS typing and
molecular detection of cfiA gene was 100% among the selected
isolates. IS elements were detected in 2 of the imipenem resistant
division II (cfiA positive) isolates. They were identified as IS942
(after inverse PCR of B. fragilis ID 7, since the amplification of the
upstream fragment of the cfiA gene gave two non-specific frag-
ments) and IS1187 (B. fragilis ID 232) following sequencing. In other
2 imipenem resistant isolates (ID 75 and ID 154), as well as in all
other non-resistant isolates, we could not confirm the presence of
IS elements. See Table 3 for details.Table 2
Antimicrobial susceptibility data among all B. fragilis isolates and among two subgroups: (
Isolates All Blood stream Non-bloo
(n¼ 623) (n¼ 47) (n¼ 576
Antibiotics S (%) I (%) R (%) NS (%) NS (%)
Penicillin 1 (0.2) 0 (0) 622 (99.8) 47 (100) (99.8)
Co-amoxiclav 571 (91.7) 12 (1.9) 40 (6.4) 7 (14.9) 45 (7.8)
Imipenem 615 (98.7) 3 (0.5) 5 (0.8) 2 (4.3) 6 (1)
Clindamycin 519 (83.3) 0 (0) 104 (16.7) 14 (29.8) 90 (15.6)
Metronidazole 623 (100) 0 (0) 0 (0) 0 (0) 0 (0)
S susceptible, I intermediate, R resistant, NS non-susceptible (IþR isolates).
n/a not applicable, pos positive, neg negative.
Please cite this article as: S. Jeverica et al., High prevalence of division
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In this study, we have successfully screened a large collection of
routine B. fragilis isolates (n¼ 623) for phylogenetic division using
MALDI-TOF MS. Overall, 8.2% prevalence of division II isolates was
detected in the two largest Slovenian tertiary care hospitals with a
marked difference in proportion of division II (cfiA positive) isolates
between blood stream and non-blood stream specimens (14.9% vs.
7.6%; p¼ 0.081), respectively. All imipenem resistant isolates
belonged to division II. One double dilution higher, but still in the
susceptible range, modal imipenem MIC was observed among di-
vision II isolates. Imipenem and co-amoxiclav non-susceptibility
were linked to division II isolates, while clindamycin non-
susceptibility was more common among blood stream isolates.
Perfect concordance betweenMALDI-TOFMS typing for division I/II
discrimination and cfiA gene detectionwas confirmed in a subset of
B. fragilis isolates from the study.
Sampling and microbiological technique have a major influence
on the isolation of anaerobic bacteria from clinical samples -
including B. fragilis [18]. For the purpose of anaerobic bacteremia
detection, we have used BACTEC Lytic blood culture bottles (Becton
Dickinson, Sparks, USA), and for the isolation of anaerobes from
other relevant specimen types (i.e. skin and soft tissue and
abdominal infections), we have used two anaerobic agar media in
combinationwith thioglycolate broth, namely Schaedler agar (non-
selective) and Schaedler Neo. Vanco. agar (selective) (bioMerieux,
Marcy-l’Etoile, France, both). A minimum of 48 h and 5 days
anaerobic incubation was used for non-blood culture specimens
and blood cultures, respectively. All isolates were identified using
MALDI Biotyper 3.1 (Bruker Daltonik, Bremen, Germany) and tested
for antimicrobial susceptibility as previously described [3]. Thus,
we can be sure that the selection of isolates used in this study is
representative of B. fragilis infections in our clinical setting.
In order to identify and differentiate between division I and II
B. fragilis, we have used a technique described by Nagy and Wybo
that is based on MALDI-TOF MS and uses specific main spectrai) blood streamvs. non-blood stream isolates and (ii) division II vs. division I isolates.
d stream p-value Division II (cfiA pos) Division I (cfiA neg) p-value
) (n¼ 51) (n¼ 572)
NS (%) NS (%)
0.775 51 (100) 571 (99.8) 0.765
0.091 13 (25.5) 39 (6.8) <0.001
0.060 8 (15.7) 0 (0) <0.001
0.012 6 (11.8) 98 (17.1) 0.325
n/a 0 (0) 0 (0) n/a
II (cfiA positive) isolates among blood stream Bacteroides fragilis in
016/j.anaerobe.2019.01.011
Table 3
Concordance betweenMALDI-TOF MS typing for division I/II discrimination and cfiA
gene detection among a selection of n¼ 30 isolates with imipenemMIC0.25mg/L.
ID MIC (imipenem) MALDI-TOF typing cfiA gene IS elementa
(mg/L) (division I/II) (±) (±)
7 32 II þ þ (IS942)
75 32 II þ e
154 32 II þ e
232 32 II þ þ (IS1187)
134 4 II þ e
220 4 II þ e
100 2 II þ e
226 2 II þ e
230 2 II þ e
190 1 II þ e
115 0.5 II þ e
208 0.5 II þ e
222 0.5 II þ e
102 0.5 II þ e
86 0.25 II þ e
103 0.25 II þ e
217 0.25 II þ e
108 1 I e nt
228 1 I e nt
81 0.5 I e nt
147 0.5 I e nt
166 0.5 I e nt
201 0.5 I e nt
91 0.25 I e nt
93 0.25 I e nt
135 0.25 I e nt
227 0.25 I e nt
233 0.25 I e nt
125 0.25 I e nt
213 0.25 I e nt
nt not tested.
a IS insertion sequence element.
S. Jeverica et al. / Anaerobe xxx (xxxx) xxx4library for division discrimination [15,19]. This technique has been
proven in several studies to be perfectly concordant with tradi-
tional molecular detection of cfiA gene [19e21,24]. It is fast, non-
costly, can be applied in real-time following bacterial identifica-
tion and in different diagnostic settings, including as a direct
identification from positive blood cultures bottles [24]. We have
used this technique on a prospectively collected mass spectra saved
in our database with a batch analysis and thus in a high-throughput
manner. However, we also prospectively collected B. fragilis isolates
with imipenem MIC 0.125mg/L for a molecular confirmation of
cfiA gene and IS element in upstream region position and for vali-
dation of the entire dataset.
The overall 8.2% prevalence rate of division II (cfiA positive)
isolates was expected and is in concordance with other studies
from the same geographic area [20,22,23,25]. However, it is difficult
to compare those proportions as it is not clear what the published
selections of isolates represent (i.e. consecutive vs. selected iso-
lates) and furthermore it has been obtained from a limited number
of isolates. Our collection is among the largest published so far
(n¼ 623) and represents consecutive and non-duplicate isolates
[26].
Our main question in this study was whether there was any
difference in the prevalence of cfiA positivity between blood stream
and non-blood stream isolates. We found a trend that cfiA positive
B. fragilis are more readily isolated from blood stream samples
(14.9% vs 7.6%), yet the difference failed to reach significance
(p¼ 0.081). This is in the contrast to the Hungarian study [19],
where they surprisingly found no cfiA positive blood culture iso-
lates. Other studies did not report on the proportion differences.
Our phenotypic antimicrobial susceptibility results are in line
with our previously published data from 2015 [3]. However, it wasPlease cite this article as: S. Jeverica et al., High prevalence of division
Slovenia as determined by MALDI-TOF MS, Anaerobe, https://doi.org/10.1very interesting to see the influence of either (i) specimen type or
(ii) division I/II type on the cumulative resistance of B. fragilis for
various tested antibiotics. A major difference in non-susceptibility
to imipenem and co-amoxiclav was found among division I/II iso-
lates which can be explained, among other reasons, by the fact that
division II isolates have cfiA gene which is not always expressed
and, that this metallo-b-lactamase is not inhibited by clavulanic
acid. These results should be read with an empirical antibiotic
therapy in mind; it may not be safe to treat division II isolates with
imipenem and possibly other carbapenems, but it may be even less
safe to empirically treat them with co-amoxiclav since approxi-
mately one quarter of them are non-susceptible. Interestingly, we
have also found almost 2-times higher proportion of clindamycin
non-susceptibility among blood stream B. fragilis (29.8% vs. 15.6%).
This leaves us with extremely narrow options for empiric therapy of
B. fragilis bacteremia/sepsis where possibly only metronidazole
would be acceptable empiric treatment option out of the five an-
tibiotics included in this study.
Several limitations of our study should be outlined. This was a
retrospective analysis based on microbiological data only. We do
not have any information on either clinical parameters or antimi-
crobial therapy of the patients. Most importantly, we have no data
regarding carbapenem therapy, which is a known selection factor
for expression of cfiA gene in division II isolates.
Nevertheless, several implications can be outlined from the re-
sults. First, we have confirmed, in the subset of isolates, that divi-
sion I/II typing is reliable with MALDI-TOF MS and that we can in
this way reliably identify B. fragilis with silent cfiA gene almost
simultaneously with species identification. Second, even though
there is still paucity of data that therapy with carbapenems is not
indicated for division II B. fragilis, it is most probably safe to say that
clinicians should be at least careful when treating those infections
with carbapenems even if the isolates are phenotypically suscep-
tible and that follow up cultures are warranted when they do so.
Third, we would discourage empiric therapy with co-amoxiclav or
carbapenems for division II isolates at least in our clinical setting.
In conclusion, a trend towards a higher proportion of division II
(cfiA positive) isolates in blood stream specimens as opposed to
non-blood stream specimens was detected (14.9% vs. 7.6%) in
Slovenia. One double-dilution higher modal imipenem MIC was
noticed among division II isolates; however, no clinical implications
can be made. Empiric therapy for division II isolates should be
locally adjusted and should not include imipenem and possibly also
other carbapenems or co-amoxiclav. Further studies focusing on
clinical consequences of infections caused by B. fragilis division II
strains are needed but until then, rapid identification and careful
treatment approach, especially for sepsis cases, is warranted.
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